New Perspectives in Preventing In-Stent Restenosis After Carotid Artery Stenting
With the increasing use of stenting for treating carotid stenosis, efforts to prevent procedural complications have intensified. The incidence of in-stent restenosis (ISR) varies widely in literature, ranging from 6% to 11% for severe stenosis (≥70%) at two years and 6% to 28% for moderate stenosis (≥50%) at one year. Although retrospective studies and meta-analyses have suggested that cilostazol reduces the rate of ISR, no randomized controlled trials were available until re cently. Therefore, Yamagami
